Given the FDA’s decision to initiate the removal of boxed warning labels from hormone therapy products, it may be prescribed ...
CK0804, a regulatory T cell therapy, received FDA orphan drug designation for myelofibrosis, supporting rare disease treatment development. Clinical study results showed significant reductions in ...
Confirmed wild-type CFTR delivery and expression in conducting airway cells of patients with class I mutations ...
As 2026 begins, a slate of high-stakes clinical readouts—from a pivotal study of Novartis’ cardiovascular candidate ...
Confirmed wild-type CFTR delivery and expression in conducting airway cells of patients with class I mutations KB407 transduction confirmed in all six patients with successful bronchoscopies irrespect ...
Early Data Suggests a Trend Toward Improvement in Pain Efficacy SASKATOON, SK, Jan. 8, 2026 /CNW/ – ZYUS Life Sciences ...
New Pharmacokinetic (PK) and Pharmacodynamic Data from Sub-Study in Phase III Trial Strengthens Scientific Basis for RenovoRx ...
Preparing for FDA approval and commercial launch of tividenofusp alfa, Denali’s TransportVehicle™ (TV)-enabled investigational therapy for Hunter ...
The FDA has granted breakthrough therapy designation (BTD) to sevabertinib (Hyrnuo, formerly BAY 2927088) for the first-line ...
Together with cash on hand, the fully leveraged facility extends Aptevo's funding runway into 2029, enabling achievement of ...
The engagement establishes a multi-phase framework to support AI enabled capital efficient development of Teverelix, a next generation GnRH antagonist, as a first in class market product for acute ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback